Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma"
Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma"
复制标题
DOI：
10.1093/jnen/61.1.58
复制
发表时间：
2002-01-01
影响因子：
3.2
通讯作者：
Louis, DN
中科院分区：
文献类型：
--
作者：
Sasaki, H;Zlatescu, MC;Louis, DN
染色体1p等位基因缺失预测少突胶质细胞肿瘤化疗敏感性增加和生存率提高。在我们医院对少突胶质细胞肿瘤1p缺失的临床试验允许LIS假设某些组织学表现与1p等位基因状态相关。44例接受基因检测的病例被转诊病理学家诊断为纯低度少突胶质细胞瘤。中枢神经病理学回顾，将该系列平均分为22例经典少突胶质细胞瘤组织学和22例更多的星形细胞特征。分子遗传学分析表明，在22个典型的少突胶质细胞瘤中有19个（86%）出现了IP丢失，在22个具有星形细胞特征的胶质细胞瘤中有16个（73%）保持了两个1P等位基因。无胶质细胞酸性蛋白阳性细胞类型（胶质细胞少突胶质细胞、小胶质细胞。细胞过程）与I β等位基因状态相关。44例病例中有14例在肿瘤进展时接受化疗：3例1p丢失的“星形细胞”胶质瘤对PCV化疗有反应，2例经典少突胶质细胞瘤维持两个1p等位基因，包括1例反应者和1例无反应者。这些结果表明，组织学外观正确预测基因型在约80%的低级别胶质瘤，但肿瘤基因型更密切地预测化疗敏感性，因此，这种客观的分子遗传学分析应纳入患者管理的低级别弥漫性胶质瘤的临床试验。
Allelic loss of chromosome 1p predicts increased chemosensitivity and better survival in oligodendroglial tumours. Clinical testing for 1p loss in oligodendroglial tumors at our hospital has allowed LIS to Postulate that certain histological appearances are associated with 1p allelic status. Forty-four cases received for genetic testing were diagnosed by referring pathologists as pure low-grade oligodendroglioma. Central neuropathological review, divided the series equally into 22 cases with classical oligodendroglioma histology and 22 with more astrocytic features. Molecular genetic analyses- demonstrated I p loss in 19 of 22 classic oligodendrogliomas (86%) and maintenance of both 1p alleles in 16 of 22 gliomas with astrocytic features (73%). No glial fibrillary acidic protein-positive cell type (gliofibrillary oligodendrocyte, minigemistocyte. cellular processes) was associated with I p allelic status. Fourteen of the 44 cases were treated with chemotherapy at tumor progression: 3 "astrocytic" gliomas with 1p loss responded to PCV chemotherapy and 2 classic oligodendrogliomas that maintained both 1p alleles included a responder and a non-responder. These results suggest that histological appearance correctly predicts genotype in approximately 80% of low-grade gliomas, but that tumor genotype more closely predicts chemosensitivity, As a result, such objective molecular genetic analyses should be incorporated into patient management into clinical trials of low-grade diffuse gliomas.